

August 02, 2025

BSE Limited

P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Subject: Press Release

Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated August 02, 2025.

This is for your information and for public at large.

Thanking you,

Yours faithfully,

For Advanced Enzyme Technologies Limited

Sanjay Basantani

Company Secretary and Head – Legal

Encl.: As above

FOR IMMEDIATE RELEASE

QUARTERLY EARNINGS RELEASE

Thane, India: Saturday, August 02, 2025

Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2025

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2025.

CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

(Amount in INR Mn.)	Q1 FY26	Q4 FY25	Q1 FY25	Change (Y-o-Y %)	Change (Q-o-Q %)	FY25	FY24	Change (%)
Revenue	1,859	1,672	1,545	20%	11%	6,369	6,239	02%
EBITDA	564	456	512	10%	24%	1,944	2,045	-05%
EBITDA Margin (%)	30%	27%	33%			31%	33%	
PAT	404	267	350	16%	51%	1,340	1,370	-02%
PAT Margin (%)	22%	16%	23%			21%	22%	
EPS	3.57	2.37	3.05	17%	51%	11.72	11.92	-02%

CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 1,859 million in the Q1 FY26 from ₹ 1,545 million in the Q1 FY25, a growth of 20%.

Profit:

Consolidated EBITDA during Q1 FY26 stands at ₹ 564 million as compared to ₹ 512 million during Q1 FY25, an increase of 10%.

Profit before tax stands at ₹ 549 million during Q1 FY26 as against ₹ 487 million in Q1 FY25, an increase of 13%.

Profit after tax grew by 16% and stands at ₹ 404 million during Q1 FY26 as compared to ₹ 350 million during the Q1 FY25.

Margin:

EBITDA margin stands at 30%, PBT margin stands at 30% and PAT margin stands at 22% during the quarter.

Financial Costs:

Financial costs stood at ₹ 8 million during Q1 FY26 as against ₹ 9 million in Q1 FY25.

Depreciation and Amortization:

Depreciation and Amortization charge for the Q1 FY26 stood at ₹ 96 million as compared to ₹ 86 million in the same quarter previous year.


Earnings Per Share:

Earnings Per Share during Q1 FY26 stands at ₹ 3.57 as compared to ₹ 3.05 in Q1 FY25.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q1 FY26	Q1 FY25	Change (%)
Human Nutrition	1,221	1,012	21%
Animal Nutrition	260	172	51%
Bio-Processing	236	251	-06%
Specialized Manufacturing	142	110	29%



The total revenue from operations grew by 20% on y-o-y basis and 11% on q-o-q basis.


The revenue from human nutrition segment increased by 21% to ₹ 1,221 million in Q1 FY26 as compared to ₹ 1,012 million in Q1 FY25. This growth is on account of robust sales in Pharma/API business.

The Animal nutrition delivered a growth of 51% to ₹ 260 million in Q1 FY26 as against ₹ 172 million in Q1 FY25.

The Bio-Processing segment declined by 6% during the quarter, it accounted for ₹ 236 million in Q1 FY26 as compared to ₹ 251 million in Q1 FY25. In this segment, food business de-grew by 11% to ₹ 174 million on y-o-y basis during Q1 FY26. The Non-Food business grew by 11% to stood at ₹ 62 million during the quarter.

The Specialized manufacturing segment contributed 7% in the pie which is around ₹ 142 million to the revenue during the quarter, higher by 29% on y-o-y basis.

Geographical Revenue:



Domestic sales accounted for ₹ 979 million in Q1 FY26 as compared to ₹ 740 million in Q1 FY25, higher by 32%.

The total revenue comprises of International sales amounting to ₹ 881 million in Q1 FY26 as compared to ₹ 806 million in Q1 FY25, an increase of 9%. The revenue declined by 4% in Americas while registered a growth of 23% in Europe, 59% in Asia (ex-India) and 61% in the rest of the world.

The domestic sales constituted about 53% of revenue from operations during Q1 FY26 as compared to 48% during Q1 FY25. International sales were 47% of revenue from operations during Q1 FY26 as compared to 52% during Q1 FY25.

CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 1,859 million in the Q1 FY26 from ₹ 1,672 million in the Q4 FY25, a growth of 11%.

Profit:

Consolidated EBITDA during Q1 FY26 stands at ₹ 564 million as compared to ₹ 456 million during Q4 FY25, higher by 24%.

Profit before tax stands at ₹ 549 million during Q1 FY26 as against ₹ 435 million in Q4 FY25, an increase of 26%

Profit after tax grew by 51% and stands at ₹ 404 million during Q1 FY26 as compared to

₹ 267 million during the Q4 FY25.

Financial Costs:

Financial costs remain unchanged and stood at ₹ 8 million during Q1 FY26 to the last quarter.

Depreciation and Amortization:

Depreciation and Amortization charge for the Q1 FY26 is ₹ 96 million as compared to ₹ 101 million in the last quarter.

Earnings Per Share:

Earnings Per Share during Q1 FY26 stands at ₹ 3.57 as compared to ₹ 2.37 in Q4 FY25.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q1 FY26	Q4 FY25	Change (%)
Human Nutrition	1,221	1,031	+19%
Animal Nutrition	260	209	+24%
Bio-Processing	236	278	-15%
Specialized Manufacturing	142	154	-08%

The human nutrition segment reflected a growth 19% to ₹ 1,221 million in Q1 FY26 as compared to ₹ 1,031 million in Q4 FY25.

Geographical Revenue:

Domestic sales accounted for ₹ 979 million in Q1 FY26 as compared to ₹ 704 million in Q4 FY25, a growth of 39%. The domestic sales constituted about 53% of revenue from operations during Q1 FY26 as compared to 42% during Q4 FY25.

The total revenue comprises of International sales amounting to ₹ 881 million in Q1 FY26 as compared to ₹ 968 million in Q4 FY25, decline of

The Animal nutrition grew by 24% to ₹ 260 million in Q1 FY26 as against ₹ 209 million in Q4 FY25.

The Bio-Processing segment underperformed by 15% during the quarter, it accounted for ₹ 236 million in Q1 FY26 as compared to ₹ 278 million in Q4 FY25. In this segment, the food business de-grew by 24% to ₹ 174 million, while non-food grew by 28% to ₹ 62 million respectively, during the quarter in comparison to Q4 FY25.

The Specialized manufacturing segment saw a decline of 8% to ₹ 142 million in Q1 FY26 from ₹ 154 million in Q4 FY25.

9%. The revenue de-grew by 13% in Americas, 10% in Europe and 2% in Asia (ex-India) while registered a growth of 19% in rest of the world.

International sales were 47% of revenue from operations during Q1 FY26 as compared to 58% during Q4 FY25.

OUTLOOK 2025-26

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

Human Nutrition:

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

Animal Nutrition:

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

Probiotics:

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal

Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

Bio Catalysis:

The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

Baking:

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

Research & Development:

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

Inorganic expansion:

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.

RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 06th August 2025, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, www.advancedenzymes.com

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: +91 22 6280 1403 / +91 22 7115 8304

Pre-registration link

For further information, please contact:

Ronak Saraf

Investor Relations

✉ ir@advancedenzymes.com

CORPORATE INFORMATION:

Advanced Enzyme Technologies Limited
Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica,
Louiswadi, Thane (W) -400 604,
Maharashtra, India
Tel.: +91 22 41703200
Fax: +91-22 25835159
Website: www.advancedenzymes.com
CIN No: L24200MH1989PLC051018